SUMMARY NURS 615 PHARM EXAM 200 ACTUAL
QUESTIONS AND CORRECT ANSWERS WITH RATIONALE
LATEST 2026 ALREADY GRADED A+ ASSURED PASS
This comprehensive set of 200 unique questions is designed to thoroughly
prepare candidates for the NURS 615 Advanced Pharmacology exam at
Maryville University. The questions cover foundational pharmacokinetic and
pharmacodynamic principles, autonomic nervous system pharmacology, and
specific drug classes for treating conditions such as diabetes, hypertension,
GERD, depression, gout, and infections. Key topics include drug interactions,
adverse effects, black box warnings, dosing considerations, and patient
education. Each entry includes a correct answer and a detailed rationale to
reinforce clinical reasoning and prescribing safety. This resource ensures
mastery of pharmacotherapeutics for advanced nursing practice, emphasizing
evidence-based decision-making and patient-centered care across diverse
populations.
1. What is the first step in the WHO 6-Step Model of Rational Prescribing?
A) Choose a treatment
B) Specify the therapeutic objective
C) Define the patient's problem
D) Start the treatment
Answer: C
Rationale: The WHO model begins with defining the patient's problem through
diagnosis. A clear diagnosis is essential before selecting or starting any treatment,
ensuring therapy is indicated and appropriate .
2. What does the mnemonic "I Can PresCribe A Drug" help clinicians remember?
A) The stages of drug development
B) The criteria for choosing an effective drug
C) The steps of pharmacokinetics
D) The types of drug interactions
Answer: B
Rationale: The mnemonic stands for Indication, Contraindication, Precautions,
Cost/Compliance, Efficacy, Adverse effects, and Dose/Duration/Direction. These
are the key criteria for selecting a safe and effective drug for a patient .
,3. What is the role of the FDA regarding dietary supplements and vitamins?
A) The FDA ensures their safety and efficacy
B) The FDA does not protect or ensure the safety of supplements and vitamins
C) The FDA approves supplements before they go to market
D) The FDA regulates supplements as strictly as prescription drugs
Answer: B
Rationale: The FDA has certain rules for supplements but they are not as stringent
as for drugs. The FDA does not ensure the safety or efficacy of dietary
supplements and vitamins before they reach the market .
4. What is off-label prescribing?
A) Prescribing a drug for a condition that is not FDA-approved
B) Prescribing a medication that is not on the hospital formulary
C) Prescribing a generic drug instead of a brand-name drug
D) Prescribing a drug without a valid diagnosis
Answer: A
Rationale: Off-label prescribing means using a medication in a manner not
specified in the FDA's approved labeling, such as for a different indication, route,
dose, or patient population. It is legal but should be supported by evidence .
5. What is the difference between pharmacodynamics and pharmacokinetics?
A) Pharmacodynamics is what the body does to the drug; pharmacokinetics is what
the drug does to the body
B) Pharmacodynamics is what the drug does to the body; pharmacokinetics is what
the body does to the drug
C) They are the same process
D) Pharmacodynamics refers to absorption; pharmacokinetics refers to excretion
Answer: B
Rationale: Pharmacodynamics describes the drug's effects on the body, including
receptor binding and mechanism of action. Pharmacokinetics describes the body's
effect on the drug through Absorption, Distribution, Metabolism, and Excretion
(ADME) .
6. What does ADME stand for in pharmacokinetics?
A) Absorption, Distribution, Metabolism, Excretion
B) Action, Distribution, Metabolism, Excretion
C) Absorption, Digestion, Metabolism, Excretion
D) Administration, Distribution, Mechanism, Excretion
Answer: A
,Rationale: ADME is the acronym for the four key pharmacokinetic processes that
determine drug concentration at the site of action: Absorption, Distribution,
Metabolism, and Excretion .
7. Which drugs cross cell membranes most easily?
A) Hydrophilic (water-loving) drugs
B) Ionized (charged) drugs
C) Lipophilic (lipid-loving) drugs
D) Large molecular weight drugs
Answer: C
Rationale: Lipophilic drugs are uncharged, non-polar, and small, allowing them to
easily cross cell membranes via passive diffusion. Most cell membranes are
lipophilic, making this the primary route for drug absorption .
8. What is the effect of hypoalbuminemia on drug distribution?
A) Increased protein binding, leading to lower free drug levels
B) Decreased protein binding, leading to higher free drug levels
C) No effect on drug distribution
D) Increased drug metabolism in the liver
Answer: B
Rationale: Hypoalbuminemia results in decreased protein binding, meaning more
free (unbound) drug is available. This can increase the risk of toxicity and adverse
effects, often requiring dose adjustments .
9. What is the primary organ responsible for drug excretion?
A) The liver
B) The lungs
C) The kidneys
D) The biliary system
Answer: C
Rationale: The kidneys are the main organs involved in drug excretion. Drugs must
be water-soluble to filter through the glomerulus. Lipid-soluble molecules are
reabsorbed and returned to the liver for further metabolism .
10. How many half-lives does it typically take for a drug to reach steady state?
A) 1-2
B) 2-3
C) 4-5
D) 6-8
Answer: C
, Rationale: It takes approximately four to five half-lives for a drug to reach steady
state, where the amount of drug administered equals the amount being eliminated.
This also applies to clearing a drug from the body .
11. What is the purpose of a loading dose?
A) To maintain steady state levels
B) To achieve a therapeutic effect more quickly
C) To reduce the risk of adverse effects
D) To prolong the duration of action
Answer: B
Rationale: A loading dose is given to rapidly achieve therapeutic drug levels,
reaching peak effect sooner than with maintenance dosing alone. It is commonly
used when a rapid response is needed .
12. What is the difference between an agonist and an antagonist?
A) An agonist blocks receptor activity; an antagonist stimulates it
B) An agonist binds and produces a response; an antagonist binds and blocks
activity
C) An agonist is always a partial agonist; an antagonist is a full agonist
D) There is no difference
Answer: B
Rationale: An agonist binds to a receptor and activates it, producing a response. An
antagonist also binds to the receptor but prevents activation, blocking the response.
Some drugs can act as both (partial agonists) .
13. What is a Type 1 hypersensitivity reaction?
A) IgG-mediated cytotoxic reaction
B) IgE-mediated reaction with rapid onset, such as anaphylaxis
C) Immune complex-mediated reaction
D) Delayed-type T-cell-mediated reaction
Answer: B
Rationale: Type 1 hypersensitivity is IgE-mediated and has a quick onset.
Examples include anaphylaxis, asthma, allergic rhinitis, urticaria, and atopic
dermatitis. Symptoms occur within minutes of exposure .
14. What is a Type 2 hypersensitivity reaction?
A) IgE-mediated anaphylaxis
B) IgG-mediated cytotoxic reaction, such as autoimmune hemolytic anemia
C) Immune complex deposition, such as serum sickness
D) T-cell-mediated delayed hypersensitivity
QUESTIONS AND CORRECT ANSWERS WITH RATIONALE
LATEST 2026 ALREADY GRADED A+ ASSURED PASS
This comprehensive set of 200 unique questions is designed to thoroughly
prepare candidates for the NURS 615 Advanced Pharmacology exam at
Maryville University. The questions cover foundational pharmacokinetic and
pharmacodynamic principles, autonomic nervous system pharmacology, and
specific drug classes for treating conditions such as diabetes, hypertension,
GERD, depression, gout, and infections. Key topics include drug interactions,
adverse effects, black box warnings, dosing considerations, and patient
education. Each entry includes a correct answer and a detailed rationale to
reinforce clinical reasoning and prescribing safety. This resource ensures
mastery of pharmacotherapeutics for advanced nursing practice, emphasizing
evidence-based decision-making and patient-centered care across diverse
populations.
1. What is the first step in the WHO 6-Step Model of Rational Prescribing?
A) Choose a treatment
B) Specify the therapeutic objective
C) Define the patient's problem
D) Start the treatment
Answer: C
Rationale: The WHO model begins with defining the patient's problem through
diagnosis. A clear diagnosis is essential before selecting or starting any treatment,
ensuring therapy is indicated and appropriate .
2. What does the mnemonic "I Can PresCribe A Drug" help clinicians remember?
A) The stages of drug development
B) The criteria for choosing an effective drug
C) The steps of pharmacokinetics
D) The types of drug interactions
Answer: B
Rationale: The mnemonic stands for Indication, Contraindication, Precautions,
Cost/Compliance, Efficacy, Adverse effects, and Dose/Duration/Direction. These
are the key criteria for selecting a safe and effective drug for a patient .
,3. What is the role of the FDA regarding dietary supplements and vitamins?
A) The FDA ensures their safety and efficacy
B) The FDA does not protect or ensure the safety of supplements and vitamins
C) The FDA approves supplements before they go to market
D) The FDA regulates supplements as strictly as prescription drugs
Answer: B
Rationale: The FDA has certain rules for supplements but they are not as stringent
as for drugs. The FDA does not ensure the safety or efficacy of dietary
supplements and vitamins before they reach the market .
4. What is off-label prescribing?
A) Prescribing a drug for a condition that is not FDA-approved
B) Prescribing a medication that is not on the hospital formulary
C) Prescribing a generic drug instead of a brand-name drug
D) Prescribing a drug without a valid diagnosis
Answer: A
Rationale: Off-label prescribing means using a medication in a manner not
specified in the FDA's approved labeling, such as for a different indication, route,
dose, or patient population. It is legal but should be supported by evidence .
5. What is the difference between pharmacodynamics and pharmacokinetics?
A) Pharmacodynamics is what the body does to the drug; pharmacokinetics is what
the drug does to the body
B) Pharmacodynamics is what the drug does to the body; pharmacokinetics is what
the body does to the drug
C) They are the same process
D) Pharmacodynamics refers to absorption; pharmacokinetics refers to excretion
Answer: B
Rationale: Pharmacodynamics describes the drug's effects on the body, including
receptor binding and mechanism of action. Pharmacokinetics describes the body's
effect on the drug through Absorption, Distribution, Metabolism, and Excretion
(ADME) .
6. What does ADME stand for in pharmacokinetics?
A) Absorption, Distribution, Metabolism, Excretion
B) Action, Distribution, Metabolism, Excretion
C) Absorption, Digestion, Metabolism, Excretion
D) Administration, Distribution, Mechanism, Excretion
Answer: A
,Rationale: ADME is the acronym for the four key pharmacokinetic processes that
determine drug concentration at the site of action: Absorption, Distribution,
Metabolism, and Excretion .
7. Which drugs cross cell membranes most easily?
A) Hydrophilic (water-loving) drugs
B) Ionized (charged) drugs
C) Lipophilic (lipid-loving) drugs
D) Large molecular weight drugs
Answer: C
Rationale: Lipophilic drugs are uncharged, non-polar, and small, allowing them to
easily cross cell membranes via passive diffusion. Most cell membranes are
lipophilic, making this the primary route for drug absorption .
8. What is the effect of hypoalbuminemia on drug distribution?
A) Increased protein binding, leading to lower free drug levels
B) Decreased protein binding, leading to higher free drug levels
C) No effect on drug distribution
D) Increased drug metabolism in the liver
Answer: B
Rationale: Hypoalbuminemia results in decreased protein binding, meaning more
free (unbound) drug is available. This can increase the risk of toxicity and adverse
effects, often requiring dose adjustments .
9. What is the primary organ responsible for drug excretion?
A) The liver
B) The lungs
C) The kidneys
D) The biliary system
Answer: C
Rationale: The kidneys are the main organs involved in drug excretion. Drugs must
be water-soluble to filter through the glomerulus. Lipid-soluble molecules are
reabsorbed and returned to the liver for further metabolism .
10. How many half-lives does it typically take for a drug to reach steady state?
A) 1-2
B) 2-3
C) 4-5
D) 6-8
Answer: C
, Rationale: It takes approximately four to five half-lives for a drug to reach steady
state, where the amount of drug administered equals the amount being eliminated.
This also applies to clearing a drug from the body .
11. What is the purpose of a loading dose?
A) To maintain steady state levels
B) To achieve a therapeutic effect more quickly
C) To reduce the risk of adverse effects
D) To prolong the duration of action
Answer: B
Rationale: A loading dose is given to rapidly achieve therapeutic drug levels,
reaching peak effect sooner than with maintenance dosing alone. It is commonly
used when a rapid response is needed .
12. What is the difference between an agonist and an antagonist?
A) An agonist blocks receptor activity; an antagonist stimulates it
B) An agonist binds and produces a response; an antagonist binds and blocks
activity
C) An agonist is always a partial agonist; an antagonist is a full agonist
D) There is no difference
Answer: B
Rationale: An agonist binds to a receptor and activates it, producing a response. An
antagonist also binds to the receptor but prevents activation, blocking the response.
Some drugs can act as both (partial agonists) .
13. What is a Type 1 hypersensitivity reaction?
A) IgG-mediated cytotoxic reaction
B) IgE-mediated reaction with rapid onset, such as anaphylaxis
C) Immune complex-mediated reaction
D) Delayed-type T-cell-mediated reaction
Answer: B
Rationale: Type 1 hypersensitivity is IgE-mediated and has a quick onset.
Examples include anaphylaxis, asthma, allergic rhinitis, urticaria, and atopic
dermatitis. Symptoms occur within minutes of exposure .
14. What is a Type 2 hypersensitivity reaction?
A) IgE-mediated anaphylaxis
B) IgG-mediated cytotoxic reaction, such as autoimmune hemolytic anemia
C) Immune complex deposition, such as serum sickness
D) T-cell-mediated delayed hypersensitivity
